Proven Efficacy in the Acute Treatment of Migraine
Pivotal trials in Europe and the United States.
The efficacy of CAMBIATM (diclofenac potassium for oral solution) in the treatment of migraine has been proven in 2 clinical trials and across multiple measures. The evaluation of CAMBIA in the most recent of those trials was based on all 4 primary end points now mandated by the US Food and Drug Administration for the evaluation of every proposed migraine treatment—pain, nausea, photophobia, and phonophobia.1
In the United States...
The onset of analgesic effect for CAMBIA was 45 minutes faster than that of diclofenac potassium tablets.
“The results demonstrate that diclofenac potassium sachets offer patients suffering from migraine pain benefits of clinical importance . . .”
— Diener et al
» CAMBIA Full Prescribing Information including boxed warning